Search - tctmd.com

Displaying 61 - 80 of 128

Sort: Relevancy | Date

Presentation TCT 2017

Facebook and Twitter for Trial Recruitment: SCAD Case Example

Presenter: Ori Ben-Yehuda, Robert A. Harrington, Roxana Mehran, Jacqueline Saw

October 30, 2017

Presentation TCT 2017

Making the EHR Useful For Research: ADAPTABLE

Presenter: Ori Ben-Yehuda, Robert A. Harrington, Roxana Mehran, Adrian F Hernandez

October 30, 2017

Presentation TCT 2017

Keeping It Simple: Large Pragmatic Trials

Presenter: Ori Ben-Yehuda, Robert A. Harrington, Roxana Mehran

October 30, 2017

Presentation TCT 2017

The Inflammatory Hypothesis After CANTOS: CIRT

Presenter: Bernard J. Gersh, Robert A. Harrington, Wolfgang Koenig

October 30, 2017

Presentation TCT 2017

The LDL Hypothesis Post FOURIER: Heading Home From ODYSSEY

Presenter: Bernard J. Gersh, Robert A. Harrington, Wolfgang Koenig

October 30, 2017

Presentation TCT 2017

Should Alleviating ISCHEMIA Be the Goal?

Presenter: Bernard J. Gersh, Robert A. Harrington, David J. Moliterno

October 30, 2017

Presentation TCT 2017

Primary Prevention in High Risk Patients II: THEMIS

Presenter: Bernard J. Gersh, Robert A. Harrington

October 30, 2017

Presentation TCT 2017

Primary Prevention In High Risk Patients I: REPRIEVE

Presenter: Bernard J. Gersh, Robert A. Harrington, Pamela S. Douglas

October 30, 2017

Presentation TCT 2017

Predicting The Future: Will the Ongoing COAPT Trial Change How We Treat Patients With Secondary MR in Heart Failure?

Presenter: David H. Adams, Ted Feldman, Gilles Dreyfus

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing TAVR UNLOAD and Early TAVR Trials Change the Threshold for TAVR in Moderate and Asymptomatic Aortic Stenosis?

Presenter: David H. Adams, Ted Feldman, Allan Schwartz

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing GALILEO and ENVISAGE AF Trials Change How We Anticoagulate Patients After TAVR?

Presenter: David H. Adams, Ted Feldman, Vinod H. Thourani

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing LOW RISK TAVR Trials Change How We Treat Low Surgical Risk Patients With Aortic Stenosis?

Presenter: David H. Adams, Ted Feldman, Craig R. Smith

October 30, 2017

Presentation TCT 2017

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

Presenter: C. Michael Gibson, Stephan Windecker

October 30, 2017

Presentation TCT 2017

Predicting The Future: Will the ABSORB III/IV Ten-Year Results Change How We Currently View Bioresorbable Vascular Scaffolds?

Presenter: C. Michael Gibson, Stephan Windecker, Stephan Achenbach

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing TWILIGHT and GLOBAL LEADERS Trials Change The Current Recommended Approach to Chronic Antiplatelet Therapy?

Presenter: C. Michael Gibson, Stephan Windecker, Eric R. Bates

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing COMPLETE Trial Change the Current Recommended Approach to Multivessel Disease in STEMI?

Presenter: C. Michael Gibson, Stephan Windecker, David Hildick-Smith

October 30, 2017

Presentation TVT 2017

Potential Barriers to Adopting a Minimalist Transfemoral TAVR Pathway: Emerging Solutions and Future Directions (3M Trial Updates)

Presenter: Axel Linke, Bernard Prendergast, David A. Wood

June 16, 2017

Presentation AHA 2016

FUnctional Testing Underlying REvascularization: The FUTURE trial

Presenter: Gilles Rioufol

November 15, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

Presenter: Philip M. Urban, Stephen G. Worthley, Robert-Jan van Geuns

November 01, 2016

Presentation TCT 2016

Direct Annuloplasty II: Mitralign Trial Results and Future Directions

Presenter: Ted Feldman, Scott Lim, Azeem Latib

October 31, 2016

Advertisement

Facebook and Twitter for Trial Recruitment: SCAD Case Example

Making the EHR Useful For Research: ADAPTABLE

Keeping It Simple: Large Pragmatic Trials

The Inflammatory Hypothesis After CANTOS: CIRT

The LDL Hypothesis Post FOURIER: Heading Home From ODYSSEY

Should Alleviating ISCHEMIA Be the Goal?

Primary Prevention in High Risk Patients II: THEMIS

Primary Prevention In High Risk Patients I: REPRIEVE

Predicting The Future: Will the Ongoing COAPT Trial Change How We Treat Patients With Secondary MR in Heart Failure?

Predicting the Future: Will the Ongoing TAVR UNLOAD and Early TAVR Trials Change the Threshold for TAVR in Moderate and Asymptomatic Aortic Stenosis?

Predicting the Future: Will the Ongoing GALILEO and ENVISAGE AF Trials Change How We Anticoagulate Patients After TAVR?

Predicting the Future: Will the Ongoing LOW RISK TAVR Trials Change How We Treat Low Surgical Risk Patients With Aortic Stenosis?

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

Predicting The Future: Will the ABSORB III/IV Ten-Year Results Change How We Currently View Bioresorbable Vascular Scaffolds?

Predicting the Future: Will the Ongoing TWILIGHT and GLOBAL LEADERS Trials Change The Current Recommended Approach to Chronic Antiplatelet Therapy?

Predicting the Future: Will the Ongoing COMPLETE Trial Change the Current Recommended Approach to Multivessel Disease in STEMI?

Potential Barriers to Adopting a Minimalist Transfemoral TAVR Pathway: Emerging Solutions and Future Directions (3M Trial Updates)

FUnctional Testing Underlying REvascularization: The FUTURE trial

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

Direct Annuloplasty II: Mitralign Trial Results and Future Directions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content